The U.S. Preventive Services Task Force (USPSTF) issued updated recommendations for HIV prophylaxis classifying all three currently available pre-exposure prophylaxis (PrEP) medications as grade A recommendations.
The previous recommendations, issued in 2019, gave a grade A recommendation to the daily oral agent emtricitabine-tenofovir disoproxil fumarate (FTC/TDF; Truvada, Gilead). The new recommendations also include the daily oral drug FTC-tenofovir alafenamide (FTC/TAF; Descovy,